Table 1.
Summary of different characteristics of the S1P modulators.
| Drug | Receptor Selectivity | Genotyping Needed | Dosing | Elimination T1/2 | Lymphocyte Restoration after Discontinuation |
|---|---|---|---|---|---|
| Fingolimod (Gilenya®) (FTY720) |
S1PR1 S1PR3 S1PR4 S1PR5 |
No | 0.5 mg/d | 7 days | 6 weeks |
| Siponimod (Mayzent®) (BAF312) |
S1PR1 S1PR5 |
Yes | Depending on genotype: CYP2C9*1*1 and CYP2C9*1*2: 2mg/d CYP2C9*2*2 and CYP2C9*1*3: 1mg/d CYP2C9*2*3 and CYP2C9*3*3: contraindicated |
30 h | 1–10 days |
| Ozanimod (Zeposia®) (RPC1063) |
S1PR1 S1PR5 |
No | 0.92 mg/d | 19–20 h | 4–12 weeks |
| Ponesimod (Ponvory®) (ACT128800) |
S1PR1 | No | 20 mg/d | 33 h | 7 days |